Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens
- PMID: 20732466
- DOI: 10.1016/j.vaccine.2010.08.041
Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens
Abstract
Group B streptococcus is one of the most important pathogens in neonates, and causes invasive infections in non-pregnant adults with underlying diseases. Applying a genomic approach that relies on human antibodies we identified antigenic GBS proteins, among them most of the previously published protective antigens. In vitro analyses allowed the selection of conserved candidate antigens that were further evaluated in murine lethal sepsis models using several GBS strains. In active and passive immunization models, we identified four protective GBS antigens, FbsA and BibA, as well as two hypothetical proteins, all shown to contribute to virulence based on gene deletion mutants. These protective antigens have the potential to be components of novel vaccines or targets for passive immune prophylaxis against GBS disease.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner.Vaccine. 2011 May 31;29(24):4116-24. doi: 10.1016/j.vaccine.2011.03.100. Epub 2011 Apr 13. Vaccine. 2011. PMID: 21496467
-
BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus.J Infect Dis. 2009 Aug 15;200(4):564-70. doi: 10.1086/603540. J Infect Dis. 2009. PMID: 19586417
-
BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood.Mol Microbiol. 2007 Feb;63(3):754-67. doi: 10.1111/j.1365-2958.2006.05555.x. Epub 2007 Jan 8. Mol Microbiol. 2007. PMID: 17212592
-
The detection of streptococcal antigens using monoclonal antibodies.Clin Lab Med. 1985 Sep;5(3):545-60. Clin Lab Med. 1985. PMID: 3899481 Review.
-
Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.Pediatr Infect Dis J. 1988 May;7(5 Suppl):S13-6. Pediatr Infect Dis J. 1988. PMID: 3041355 Review.
Cited by
-
Expression, purification and structural analysis of a fibrinogen receptor FbsA from Streptococcus agalactiae.Protein J. 2011 Mar;30(3):159-66. doi: 10.1007/s10930-011-9317-1. Protein J. 2011. PMID: 21380721
-
Development and evaluation of a multi-epitope subunit vaccine against group B Streptococcus infection.Emerg Microbes Infect. 2022 Dec;11(1):2371-2382. doi: 10.1080/22221751.2022.2122585. Emerg Microbes Infect. 2022. PMID: 36069613 Free PMC article.
-
Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model.Am J Obstet Gynecol. 2011 Sep;205(3):249.e1-8. doi: 10.1016/j.ajog.2011.06.024. Epub 2011 Jun 15. Am J Obstet Gynecol. 2011. PMID: 21802065 Free PMC article.
-
Streptococcus agalactiae Non-Pilus, Cell Wall-Anchored Proteins: Involvement in Colonization and Pathogenesis and Potential as Vaccine Candidates.Front Immunol. 2018 Apr 5;9:602. doi: 10.3389/fimmu.2018.00602. eCollection 2018. Front Immunol. 2018. PMID: 29686667 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources